Abstract
National Health Authority (HAS) submissions seeking market access of a drug in France require demonstration of its additional benefit, based on direct or indirect treatment comparisons (ITC). Transparency Committee (TC) and Economic and Public Health Committee (CEESP) requirements may differ based on their respective guidelines. The objective of this analysis is to perform a critical assessment of ITC methods submitted compared to HAS final appraisal for both committees.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
